GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile
Radium 223 Dichloride Reduces Death Risk By 30 Percent in Castration-Resistant Disease
Survey Finds 70 Percent of Oncologists Prescribe Avastin Off-Label For Ovarian Cancer
CMX001 Reduces Adenovirus Progression and Viremia
Biomarker Identified Predicting Graft-Versus-Host Disease Risk
Follow-up Finds Finasteride Reduces Prostate Cancer Risk Without Affecting Lifespan
Study Shows Early Treatment Of Asymptomatic Myeloma Can Improve Survival
Pretreatment with Azacitidine Achieves 28-Month Remission
Specific Pathology Pattern Can Predict Recurrence
20% of Women Do Not Believe Tailored Risk Assessments
Circulating Tumor Cells Predict Treatment Resistance In Study Of Metastatic Breast Cancer
Study Finds Gene Expression Test Predicts Stage I or II Recurrence
NCI CTEP Approved Trials For the Month of August
FDA Grants Orphan Designation To E7777 in T-Cell Lymphoma
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ
